Latest Biotechnology, Pharmaceutical and Healthcare News from PhRMA

18:23 EDT 19th March 2018 | BioPortfolio

Here are the most relevant search results for "PhRMA" found in our extensive news archives from over 250 global news sources.

More Information about PhRMA on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PhRMA for you to read. Along with our medical data and news we also list PhRMA Clinical Trials, which are updated daily. BioPortfolio also has a large database of PhRMA Companies for you to search.

Showing News Articles 1–25 of 204 from PhRMA

Thursday 18th January 2018

340B Spotlight: New pieces of legislation continue momentum to fix 340B program

In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters introduced the 340B PAUSE Act, and just this week, Sena

Wednesday 17th January 2018

PhRMA urges CMS to share the savings with seniors

Yesterday, PhRMA submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) Request for Information (RFI) on sharing a portion of manufacturer rebates directly with beneficiaries at the point of sale.   

Friday 12th January 2018

ICYMI: Why 2017 medicine approvals matter

This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary milestone for the biopharmaceutical industry and

Wednesday 10th January 2018

Clarity around anti-kickback statute needed to promote innovative payment arrangements

You may have recently read about how biopharmaceutical companies and insurers are working together to implement new approaches to paying for medicines, including through results-based contracts (RBCs), which link reimbursement to real

Monday 18th December 2017

Medicare Monday: Helping beneficiaries access vaccines

Last month, we released a State of Vaccines report, as well as an update to our Medicines in Development for Vaccines report, which shared exciting information about the 264 vaccines currently in development by America’s biopharmaceutical companies. These include vaccines for

Tuesday 12th December 2017

NHE Data: Medicine spending grew just 1.3 percent in 2016

According to new data from the National Health Expenditures (NHE), retail medicine spending grew just 1.3 percent in 2016, down from 9 percent in 2015. To put that in context, total spending for hospitals grew more than 3.5 times that amount. This data, recently published in Health Affairs, reaffirms how our nation’s competitive marketplace for medicines controls costs while supporti...

Monday 11th December 2017

ICYMI –Report highlights increasing prevalence for Alzheimer’s disease

The number of Americans affected by Alzheimer’s disease (AD) continues to rise according to a new report.1 Researchers found that approximately 6.08 million Americans had Alzheimer’s or mild

Wednesday 6th December 2017

New surveys find payers and providers want more data from biopharmaceutical companies

Both payers and providers are interested in additional information from biopharmaceutical companies about prescription medicines – including information about pipeline medicines and unapproved uses of approved medicines. This finding is from a recent survey of payer executives and specialty physicians conducted by Health Strategi

Friday 1st December 2017

World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation

Today marks World AIDS Day, a moment to reflect on the significant advances made in the treatment and prevention of HIV, the virus which causes AIDS. The incredible scientific progress biopharmaceutical companies have made in the last 30 years has led to an 88 percent decline in the

Wednesday 29th November 2017

EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing

Stakeholders are gathering in London this week for a workshop entitled Data Anonymization – a Key Enabler for Clinical Data Sharing. The workshop, jointly organized by the European Medicines Agency (EMA) and the Multi-Regional Clinical Trials Center of Brigham and

Tuesday 28th November 2017

Guest Post: Film chronicles clinical trials ‘paying it forward’

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no ...

Wednesday 22nd November 2017

Supporting opportunities for enhanced competition in the marketplace

Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into the marketplace. Thanks in part to the incentives in the law, 90 percent of prescriptions today are filled with generi

Tuesday 21st November 2017

New report shows better diabetes management saves money and improves patient outcomes

A recent IHS Markit report, “The Clinical and Economic Benefits of Better Treatment of Adult Medicaid Beneficiaries with Diabetes,” simulated savings in the Medicaid program as a result of better management of diabetes. The study found that controlling blood pressure, total

Monday 20th November 2017

Medicare Monday: PhRMA’s comments on new direction for CMMI

Today, PhRMA submitted its comments in response to the Centers for Medicare & Medicaid Services (CMS) request for information on the future of the Center for Medicare and Medicaid Innovation (CMMI). While well intentioned, CMMI’s current flexibility to make far-reaching changes has raised a number of concerns about large-scale mandatory demonstrations developed without stakeholde...

Monday 13th November 2017

Medicare Monday: Same bad ideas continue to threaten Part D and beneficiary access to medicines

Perhaps the biggest fact that is often overlooked about Part D is that there is already significant price negotiation in the program. Thanks to Part D’s competitive structure, large purchasers often negotiate steep discounts and rebates with prescription drug man

Video: What is a results-based contract?

New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies are working with insurers to develop new ways to pay for medicines.

Saturday 11th November 2017

Honoring veterans serving in the biopharmaceutical industry

In honor of Veterans Day, we spoke with Rob Caskey, a senior manager in PhRMA’s finance department about his military service, journey to PhRMA and why veterans make great employees for America’s biopharmaceutical companies.

Thursday 9th November 2017

New report and event examine the new era of vaccines

Today, leading minds will come together for an in-depth conversation centered on vaccines – their critical role in warding off disease, the innovative science powering breakthroughs in their research and what their future might look like.

Wednesday 1st November 2017

A new era in cancer

The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment. Next week, on Wednesday, November 8, leading minds in the fight against cancer will come together in Philadelphia for a conversation led by Axios titled, “Future Shapers: A New Era in Cancer Care.” The event is sponsored as part of Ph...

Monday 30th October 2017

Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI

In case you missed it, earlier this month, the Center for Medicare & Medicaid Services formally withdrew a controversial proposal that would have had a detrimental impact on patient access to lifesaving treatments covered under Part B,

Tuesday 24th October 2017

Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes

Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study comparing the effectiveness of oral and injectable disease-modifying therapies for patients with multiple sclerosis.

Friday 20th October 2017

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have taken notice. Just last week, the House Energy and Commerce Subcommittee on Oversight and Investigations held a hearing to examine how the 340B program is being used by 340B covered entitie...

Wednesday 18th October 2017

The Washington Post retracts PhRMA claim in opioid story

Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its enactment. As stated previously, these claims are unequivocally false and last nig

Tuesday 17th October 2017

Excerpts from testimony by PhRMA’s Lori Reilly

Today, Lori Reilly, executive vice president for policy, research and membership at the Pharmaceutical Research and Manufacturers of America (PhRMA), testified at the U.S. Senate Committee on Health, Education Labor and Pensions about understanding the role the drug delivery system plays in determining what patients pay for medicines. 

How much are hospitals marking up the price of medicines? The answer may surprise you.

Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). The analysis of 20 medicines also found the amount hospitals receive after negotiations with commercial payers is, on average, more than 250 percent what they paid to acquire the ...

Quick Search


News Quicklinks